Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBS-NN/NN2 vaccine in healthy females
NCT03807245Phase 1Completed
- Sponsor
- MinervaX
- Start
- Jan 2019
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GBS-NN/NN2 vaccine in Group B streptococcal infection (GBS) (4 arms), sponsored by MinervaX. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events at 85 days. Started Jan 2019; status: completed.
02
Drugs
GBS-NN/NN2 vaccine
03
Conditions
Group B streptococcal infection (GBS)
Beyond the preview
Go deeper on NCT03807245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03807245.